SCHEMBL209097

SCHEMBL209097

O=C1C[CH]Oc2ccccc21

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOB P27338 6/20 0.43
ADORA3 P0DMS8 3/20 0.43
KDM4E B2RXH2 2/20 0.43
AR P10275 2/20 0.43
CYP19A1 P11511 2/20 0.43
HSD17B10 Q99714 1/20 0.43
PKM P14618 1/20 0.42
TSHR P16473 1/20 0.42
TDP1 Q9NUW8 2/20 0.40
LMNA P02545 1/20 0.40
NPC1 O15118 3/20 0.38
RAB9A P51151 3/20 0.38
MAPT P10636 2/20 0.38
HSD11B1 P28845 1/20 0.38
AKR1C3 P42330 1/20 0.38
CYP3A4 P08684 1/20 0.38
MAPK1 P28482 1/20 0.38
ALOX15 P16050 1/20 0.37
AXL P30530 1/20 0.35
MEN1 O00255 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7485483 0.79 MAOB (0.41) MAOBADORA3KDM4EARCYP19A1
SCHEMBL8104524 0.79 MAOB (0.41) MAOBADORA3KDM4EARCYP19A1
SCHEMBL9411043 0.69 RAD52 (0.44) KDM4EHSD17B10PKMTSHRTDP1
SCHEMBL19467520 0.69 KDM4E (0.49) KDM4EPKMTSHRTDP1LMNA
SCHEMBL9411044 0.69 RAD52 (0.44) KDM4EHSD17B10PKMTSHRTDP1
SCHEMBL25287682 0.69 MAOB (0.40) MAOBADORA3KDM4EARCYP19A1
3-Coumaranone SCHEMBL69412 0.68 PKM (0.56) MAOBADORA3KDM4EARCYP19A1
3-Coumaranone SCHEMBL29420742 0.68 PKM (0.56) MAOBADORA3KDM4EARCYP19A1
SCHEMBL9411160 0.67 RAD52 (0.33) KDM4EPKMMAPT
SCHEMBL9411157 0.67 RAD52 (0.33) KDM4EPKMMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 280 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11572384-B2 Unusual substrates of tubulin tyrosine ligase FORSCHUNGSVERBUND BERLIN E.V. (DE) 2023-02-07 US claimed
US-20190144493-A1 UNUSUAL SUBSTRATES OF TUBULIN TYROSINE LIGASE FORSCHUNGSVERBUND BERLIN E.V. (DE) 2019-05-16 US claimed
WO-2017186855-A1 UNUSUAL SUBSTRATES OF TUBULIN TYROSINE LIGASE FORSCHUNGSVERBUND BERLIN E.V. (DE) 2017-11-02 WO claimed
US-20090239857-A1 TRIAMINE DERIVATIVE DAIICHI SANKYO COMPANY, LIMITED (JP) 2009-09-24 US claimed
US-7576135-B2 Diamine derivatives DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2009-08-18 US claimed
EP-1864982-A1 TRIAMINE DERIVATIVE DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2007-12-12 EP claimed
US-20070129371-A1 Novel ethylenediamine derivatives DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2007-06-07 US claimed
US-20060252837-A1 Cyclic diamine derivatives useful as agents for preventing and/or treating cerebral infarction, cerebral embolism, myocardial infarction, angina pectoris, pulmonary infarction, pulmonary embolism; inhibit activated blood coagulation factor X DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2006-11-09 US claimed
CN-1829709-A Bicyclic imidazol derivatives against flaviviridae GENELABS TECH INC (US) 2006-09-06 CN claimed
US-20050245565-A1 Diamine derivatives DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2005-11-03 US claimed
US-20050020645-A1 Diamine derivatives DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2005-01-27 US claimed
EP-1415992-A1 DIAMINE DERIVATIVES DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2004-05-06 EP claimed
EP-1405852-A1 DIAMINE DERIVATIVES DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2004-04-07 EP claimed
US-6096895-A Heterocyclic dihydrazole compounds and their use for controlling fungal plant diseases E. I. DU PONT DE NEMOURS AND COMPANY (US) 2000-08-01 US claimed
US-6057352-A CONTROLLING PLANT DISEASES CAUSED BY FUNGAL PLANT PATHOGENS E. I. DU PONT DE NEMOURS AND COMPANY (US) 2000-05-02 US claimed
WO-1996036229-A1 FUNGICIDAL CYCLIC AMIDES E.I. DU PONT DE NEMOURS AND COMPANY (US) 1996-11-21 WO claimed
WO-1996033180-A1 OXAZOLINE AND THIAZOLINE ARTHROPODICIDES E.I. DU PONT DE NEMOURS AND COMPANY (US) 1996-10-24 WO claimed
EP-0045165-B1 RHODANINE DERIVATIVES, A PROCESS FOR THEIR PREPARATION, AND ALDOSE REDUCTASE INHIBITORS CONTAINING SUCH DERIVATIVES ONO PHARMACEUTICAL CO., LTD. (JP) 1986-03-12 EP claimed
EP-0047109-B1 RHODANINE DERIVATIVES, PROCESS FOR THEIR PREPARATION, AND ALDOSE REDUCTASE INHIBITOR CONTAINING THE RHODANINE DERIVATIVES AS ACTIVE INGREDIENT ONO PHARMACEUTICAL CO., LTD. (JP) 1985-01-02 EP claimed
EP-0047109-A1 Rhodanine derivatives, process for their preparation, and aldose reductase inhibitor containing the rhodanine derivatives as active ingredient ONO PHARMACEUTICAL CO., LTD. (JP) 1982-03-10 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070129371-A1 Novel ethylenediamine derivatives C1R, C9, C1S MAOB 1441/4885ADORA3 1683/4885KDM4E 3425/4885
US-20090239857-A1 TRIAMINE DERIVATIVE F2, F12, F3 MAOB 208/4885ADORA3 268/4885KDM4E 2715/4885
US-20060252837-A1 Cyclic diamine derivatives useful as agents for preventing and/or treating cerebral infarction, cerebral embolism, myocardial infarction, angina pectoris, pulmonary infarction, pulmonary embolism; inhibit activated blood coagulation factor X F2, C1S, C9 MAOB 2043/4885ADORA3 1584/4885KDM4E 3761/4885
US-20050020645-A1 Diamine derivatives C9, C1S, C1R MAOB 2147/4885ADORA3 1740/4885KDM4E 3971/4885
US-20050245565-A1 Diamine derivatives C9, C1S, C1R MAOB 2147/4885ADORA3 1740/4885KDM4E 3971/4885
US-11572384-B2 Unusual substrates of tubulin tyrosine ligase TTL, TUBA1C, TUBB6 MAOB 3302/4885ADORA3 4781/4885KDM4E 3557/4885
US-20190144493-A1 UNUSUAL SUBSTRATES OF TUBULIN TYROSINE LIGASE TTL, TUBA1C, TUBB6 MAOB 3302/4885ADORA3 4781/4885KDM4E 3557/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.